| Drug General Information |
| Drug ID |
D00UZR
|
| Former ID |
DCL000365
|
| Drug Name |
PD-332991
|
| Synonyms |
LQQ; PD 0332991; PD0332991; PD-0332991; PD 332991, PD 0332991, PD0332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 2 |
[1]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Company |
Onyx Pharmaceuticals; Pfizer
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C24H29N7O2
|
| Canonical SMILES |
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCC<br />C5)C(=O)C
|
| InChI |
1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
|
| InChIKey |
AHJRHEGDXFFMBM-UHFFFAOYSA-N
|
| CAS Number |
CAS 571190-30-2
|
| PubChem Compound ID |
|
| PubChem Substance ID |
8035907, 11062094, 11538604, 12015755, 14808444, 17137183, 39302900, 46394060, 57361299, 78833389, 99436913, 103461613, 103905660, 103905661, 113915142, 121280258, 124360805, 124757012, 125164718, 126580155, 126671645, 126737419, 131480762, 134339015, 134339302, 134339471, 134964422, 135262045, 135686212, 135686213, 135686228, 135686229, 136367313, 136367838, 136920362, 137184856, 137275973, 141483504, 143498887, 144116345, 152240013, 152258827, 152344089, 160647678, 162202562, 164045126, 172232465, 172919351, 177748911, 178103952
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 4 |
Target Info |
Modulator |
|
|---|
| Cell division protein kinase 6 |
Target Info |
Modulator |
|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Tight junction
|
|
T cell receptor signaling pathway
|
|
Hepatitis B
|
|
Measles
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Pancreatic cancer
|
|
Glioma
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancerhsa04110:Cell cycle
|
|
MicroRNAs in cancer
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Validated targets of C-MYC transcriptional activation
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of retinoblastoma proteinp73pathway:p73 transcription factor network
|
|
Coregulation of Androgen receptor activity
|
|
C-MYB transcription factor network
|
|
IL2 signaling events mediated by STAT5
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Oncogene Induced Senescence
|
|
RMTs methylate histone arginines
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Ubiquitin-dependent degradation of Cyclin D1
|
|
Cyclin D associated events in G1
|
|
Meiotic recombinationR-HSA-2559580:Oxidative Stress Induced Senescence
|
|
WikiPathways
|
DNA Damage Response
|
|
G1 to S cell cycle control
|
|
Ovarian Infertility Genes
|
|
PPAR Alpha Pathway
|
|
Bladder Cancer
|
|
S Phase
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Meiotic Recombination
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
|
Wnt Signaling Pathway Netpath
|
|
Metastatic brain tumor
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
miRNAs involved in DNA damage response
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health. |
|---|
